Breakthrough Study Reveals Focused Ultrasound as Effective Treatment for Parkinson's Disease Relief

Groundbreaking Findings in Parkinson's Treatment

In a pivotal study recently published in The Lancet Neurology, Insightec, a leading healthcare company, has unveiled promising results regarding the use of MR-guided focused ultrasound (MRgFUS) as a treatment for Parkinson's disease. This multicenter trial is noted as the first to systematically evaluate the staged bilateral approach to MRgFUS, which has shown to deliver significant and lasting relief from motor symptoms associated with Parkinson's disease (PD).

Study Overview

Conducted across nine investigational centers, including locations in the U.S., Spain, and Taiwan, this study examined a total of 54 patients suffering from advanced Parkinson's disease. Participants underwent the MRgFUS procedure using Insightec's Exablate® Neuro system—first on one side of the brain, followed by the second side at least six months later. This staged approach allowed researchers to analyze both incremental and cumulative effects of the treatment method.

Benefits from the intervention have been quantifiable. Within just one month, patients began exhibiting marked improvements in motor function, with results maintaining stability throughout an extended follow-up period of 12 months. Specifically, the procedure has led to a stunning 66.8% reduction in overall motor complications reported three months after the bilateral treatment.

Patient Experience Reports

Patients reported a drastic drop in the duration spent experiencing dyskinesia—uncontrolled movements that severely hinder daily activities. Initially spending about 75% of their waking hours afflicted by these troublesome movements, patients reported this time falling to just 14% after the second-side procedure. Furthermore, those periods deemed